| 000 | 01576 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516011845.0 | ||
| 264 | 0 | _c20110218 | |
| 008 | 201102s 0 0 spa d | ||
| 022 | _a1606-7916 | ||
| 024 | 7 |
_a10.1590/s0036-36342010000500002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHernández-Garduño, Eduardo | |
| 245 | 0 | 0 |
_a[Comments on the article "Biological, clinical and epidemiological aspects of latent tuberculosis" by Jorge A. Barrios Payán et al.]. _h[electronic resource] |
| 260 |
_bSalud publica de Mexico _c |
||
| 300 |
_a383-4; author reply 384-5 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAntitubercular Agents _xadministration & dosage |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aDisease Transmission, Infectious _xprevention & control |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHIV Infections _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunocompromised Host |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 |
_aIsoniazid _xadministration & dosage |
| 650 | 0 | 4 |
_aLatent Tuberculosis _xdrug therapy |
| 650 | 0 | 4 |
_aMexico _xepidemiology |
| 650 | 0 | 4 |
_aObesity _xepidemiology |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aYoung Adult |
| 773 | 0 |
_tSalud publica de Mexico _gvol. 52 _gno. 5 _gp. 383-4; author reply 384-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1590/s0036-36342010000500002 _zAvailable from publisher's website |
| 999 |
_c20348787 _d20348787 |
||